Chen S, Du K, Zou C (2020) Current progress in stem cell therapy for type 1 diabetes mellitus
There is limited human data available, and its safety during pregnancy is not fully established
doi:10.1016/j.molmet.2022.101533 203
The following SGLT2is were considered in this study: canagliflozin, bexagliflozin, licogliflozin, empagliflozin, luseogliflozin, dapagliflozin, enavogliflozin, remogliflozin, ertugliflozin, ipragliflozin, henagliflozin, remogliflozin, tofogliflfozin and sotagliflozin
Building on the therapeutic success of GLP-1RAs, recent pharmacological developments have introduced GLP-1 with glucose-dependent insulinotropic polypeptide (GIP)/glucagon (GCG) dual or triple receptor agonists simultaneously target multiple incretin pathways, offering a novel multi-targeted approach to MASLD treatment